Holmes Biopharma, Inc.
OTC Bulletin Board : HLMB

Holmes Biopharma, Inc.

August 10, 2006 09:01 ET

Holmes Biopharma Expands Worldwide

SCOTTSDALE, ARIZONA--(CCNMatthews - Aug. 10, 2006) - Holmes Biopharma, Inc. (OTCBB:HLMB) announced that it is expanding its clinical research world-wide by entering into strategic alliances with existing clinics operating outside the United States.

The first alliance is between Holmes subsidiary Qualia Clinical Service Inc. and a US-based biotech company, New Life Scientific, Inc.. It involves clinical research clinics in Poland and the Ukraine. The extended geographic reach brought about by this relationship will offer a new solution for pharmaceutical companies with global service requirements.

"This is a true win-win relationship where each company stands to benefit enormously from the added technology offerings and extended global reach. Holmes will now have access to the large and rapidly growing market in Eastern Europe, and will be able to offer research services to a broader segment of the pharmaceutical industry," stated Sohail Khattak, President and CEO of Qualia.

On behalf of the Board of Directors

John F. Metcalfe, President

Certain statements in this press release constitute "forward-looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.


Contact Information